Severe Rheumatoid Arthritis (RA), Worse Outcomes, Comorbid Illness, and Sociodemographic Disadvantage Characterize RA Patients with Fibromyalgia

Journal of Rheumatology

Volumn 31, Issue 4, 2004, Pages 695-700

  Wolfe, Frederick ^a,b   Michaud, Kaleb ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

Author keywords

Costs; Etiology; Fibromyalgia; Outcome; Rheumatoid arthritis; Therapy

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PREDNISONE;

ADULT; AGED; ARTHRITIS; ARTICLE; CANCER; CARDIOVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DISABILITY; DISEASE SEVERITY; DRUG COST; ETHNIC GROUP; FATIGUE; FEMALE; FIBROMYALGIA; HOSPITAL COST; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTCOMES RESEARCH; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYMPTOMATOLOGY; VISUAL ANALOG SCALE;

ARTHRITIS, RHEUMATOID; COMORBIDITY; DEMOGRAPHY; DISABILITY EVALUATION; FATIGUE; FEMALE; FIBROMYALGIA; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 1842530444     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Croft P, Burt J, Schollum J, Thomas E, Macfarlane G, Silman A. More pain, more tender points: is fibromyalgia just one end of a continuous spectrum? Ann Rheum Dis 1996;55:482-5.
2. Croft P, Schollum J, Silman A. Population study of tender point counts and pain as evidence of fibromyalgia. BMJ 1994;309:696-9.
3. Croft P, Rigby AS, Boswell R, Schollum J, Silman A. The prevalence of chronic widespread pain in the general population. J Rheumatol 1993;20:710-3.
4. White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. J Rheumatol 1999;26:1577-85.
5. White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999;26:1570-6.
6. White KP, Harth M, Speechley M, Ostbye T. A general population study of fibromyalgia tender points in noninstitutionalized adults with chronic widespread pain. J Rheumatol 2000;27:2677-82.
7. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
8. Mengshoel AM, Forseth KO, Haugen M, Walle-Hansen R, Forre O. Multidisciplinary approach to fibromyalgia. A pilot study. Clin Rheumatol 1995;14:165-70.
9. Forseth KO, Gran JT. The prevalence of fibromyalgia among women aged 20-49 years in Arendal, Norway. Scand J Rheumatol 1992;21:74-8.
10. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
11. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in persons with rheumatoid arthritis: a 3 year study of 7527 patients. Arthritis Rheum 2003;48:2750-62.
12. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002;29:467-73.
13. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002;29:1015-22.
14. Wolfe F, Flowers N, Anderson J. The National Rheumatic Disease Data Bank: case mix and severity characteristics of patients in rheumatological practice [abstract]. Arthritis Rheum 1998;41 suppl:S132.
15. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
16. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
17. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.
18. Meenan RF, Gertman PM, Mason JH, Dunaif R. The Arthritis Impact Measurement Scales. Arthritis Rheum 1982;25:1048-53.
19. Meenan RF. The AIMS approach to health status measurement: conceptual background and measurement properties. J Rheumatol 1982;9:785-8.
20. Stucki G, Liang MH, Stucki S, Bruhlmann P, Michel BA. A self-administered rheumatoid arthritis Disease Activity Index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995;38:795-8.
21. Fransen J, Hauselmann H, Michel BA, Caravatti M, Stucki G. Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity. Arthritis Rheum 2001;44:53-60.
22. Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology Oxford 2000;39:321-7.
23. Mchorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
24. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992;30:473-83.
25. Fransen M, Edmonds J. Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. Rheumatology 1999;38:807-13.
26. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
27. EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
28. Choi HK, Michaud K, Wolfe F. Utility measures in rheumatic disorders [abstract]. Arthritis Rheum 2002;46 Suppl:S76.
29. Department of Health and Human Services. The 1998-2003 HHS poverty guidelines. Washington, DC: US Department of Health and Human Services; 2003. Internet: [cited February 9, 2004] http://aspe.hhs.gov/poverty/98poverty.htm
30. Wolfe F. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. J Rheumatol 2003;30:369-78.
31. Stata Corporation. Stata statistical software: release 8.0. College Station, TX: Stata Corp.; 2003.
32. Wolfe F, Hawley DJ. Evidence of disordered symptom appraisal in fibromyalgia: increased rates of reported comorbidity and comorbidity severity. Clin Exp Rheumatol 1999;17:297-303.
33. Macfarlane GJ, Thomas E, Papageorgiou AC, Schollum J, Croft PR, Silman AJ. The natural history of chronic pain in the community: a better prognosis than in the clinic? J Rheumatol 1996;23:1617-20.